Radiology artificial intelligence firm asks FDA to exempt certain devices from premarket review
Harrison.ai has petitioned the FDA to exempt certain radiology devices from premarket review, arguing that streamlined pathways could accelerate access to AI tools. The move has sparked mixed reactions within the healthcare community, with some AI vendors supporting faster deployment while radiologists and patient groups warn it could compromise safety and oversight.
Proponents contend that AI-powered radiology devices can improve efficiency and clinical decision-making, suggesting existing regulatory processes hinder innovation and timely patient care. Critics argue that bypassing premarket review may reduce upholding of rigorous safety and effectiveness standards, risking incorrect diagnoses or missed findings.
The discussion centers on balancing innovation with patient safety, as stakeholders debate how to calibrate regulatory oversight for evolving AI technologies in medical imaging.